<div id="readability-page-1"><div><p>Vaxart (VXRT) is drawing fresh attention ahead of its scheduled presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026. Investors will be listening for pipeline and funding updates.</p> <p>See our latest analysis for Vaxart.</p> <p>Vaxart’s recent 34.83% 7 day share price return and 102.97% 90 day share price return point to building momentum ahead of the conference, even as the 5 year total shareholder return of 87.31% highlights longer term challenges.</p> <p>If this conference driven move has your attention, it could be a good moment to widen your watchlist with 29 healthcare AI stocks that our screener has surfaced as potential new ideas.</p> <p>With the stock at US$0.75 against a US$3.00 analyst target and recent returns swinging sharply, investors may be asking whether Vaxart is quietly undervalued ahead of its conference update or whether the market is already pricing in future growth.</p> <h2>Most Popular Narrative: 81.2% Undervalued</h2> <p>At a last close of $0.75 against a narrative fair value of $4.00, the most followed view on Vaxart is setting very high expectations.</p> <blockquote> <p><em>The large, fully enrolled Phase IIb COVID 19 trial with around 5,400 participants and two planned data readouts in 2026 may create a series of clinical events that, if favorable, could support future royalty streams and potential net margin expansion through partner led commercialization.</em></p> </blockquote> <p><em>Read the complete narrative.</em></p> <p>Curious how a loss making vaccine developer ends up with such a punchy fair value? The narrative leans heavily on margin expansion, revenue rebuilding and a rich future earnings multiple. The exact mix of those assumptions might surprise you.</p> <p><strong>Result: Fair Value of $4.00 (UNDERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, you still need to weigh the risk that BARDA’s stop work order on the COVID 19 trial and its reliance on fresh funding could quickly weaken this bullish setup.</p> <p>Find out about the key risks to this Vaxart narrative.</p> <h2>Another Angle: Ratios Flash A Different Signal</h2> <p>Those bullish fair value narratives sit awkwardly next to the current trading multiples. Vaxart trades on a P/S of 1.2x, while the fair ratio is just 0.1x, and both the US Biotechs industry at 12.5x and peers at 25.8x tell very different stories about what the market might adjust toward. Is this a setup for a repricing or a value trap in waiting?</p> <p>See what the numbers say about this price — find out in our valuation breakdown.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8eb6e44b-1617-4cdd-977b-cdef90866846/chart/ps-multiple-vs-industry/query-ZGF0ZT0yMDI2LTAyLTI3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8eb6e44b-1617-4cdd-977b-cdef90866846/chart/ps-multiple-vs-industry/query-ZGF0ZT0yMDI2LTAyLTI3"/><figcaption>OTCPK:VXRT P/S Ratio as at Feb 2026</figcaption></figure><h2>Next Steps</h2> <p>If this mix of optimism and caution feels hard to balance, it may help to review the data yourself and be ready to act as sentiment shifts. To round out the picture, take a closer look at 3 important warning signs.</p> <h2>Looking for more investment ideas?</h2> <p>If Vaxart is on your radar, this is a good time to scan a few more ideas so you are not relying on a single story.</p> <ul> <li>Target potential turnaround opportunities by checking out 54 high quality undervalued stocks that our filters flag as trading below their implied worth with supporting fundamentals.</li> <li>Prioritise resilience first and see 80 resilient stocks with low risk scores that score well on our risk checks so you can focus on steadier profiles.</li> <li>Review our screener containing 24 high quality undiscovered gems that pair financial strength with relatively low market attention.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

<p>Vaxart (VXRT) is gaining investor attention ahead of its presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026. The stock has seen a 34.83% return over the past week and a 102.97% return over the past 90 days, raising questions about its valuation. Analysts set a target price of $3.00, while the stock trades at $0.75, suggesting it may be undervalued. However, risks include a stop work order on its COVID-19 trial and reliance on new funding. Investors are advised to consider additional opportunities in the healthcare sector.</p>

Simplywall

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

SPDR S&P Biotech

Vaxart

VG Health

Ark Genomic Revolution ETF

iShares Global Healthcare

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Direxion S&P Biotech Bear 3X

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

Assessing Vaxart (VXRT) Valuation As Conference Presentation Draws Increased Investor Attention